16 enrolling by invitation. 16 Phase 2, 6 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Enrolling by invitation 16 |
| Phase 1 | 6 | Enrolling by invitation 6 |
| Phase 3 | 2 | Enrolling by invitation 2 |
Follow Gastrointestinal Diseases: new trials by email Literature Review of Gastrointestinal Diseases trials Research Report on Gastrointestinal Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Herbal Supplement (Biocidin REMOVE) for Bacterial Overgrowth in Irritable Bowel Syndrome Biocidin REMOVE, Placebo - Irritable Bowel Syndrome (IBS), Small Intestinal Bacterial Overgrowth Syndrome (SIBO) | Phase 2 | Enrolling by invitation | Johns Hopkins University | 40 | 2026-10-26 | 2026-11-03 |
| Shortening Radiation Course Duration Using Simultaneous Integrated Boost With Lower Intensity Elective Nodal Dosing and Concurrent Chemotherapy for High-Risk Anal Squamous Cell Carcinoma Hypofractionated Radiation Therapy - Anal Cancer | Phase 2 | Enrolling by invitation | University of Vermont Medical Center | 24 | 2026-08-26 | 2026-09-15 |
| Seaweed Extract (Fucoidan) for Gut Inflammation in Ulcerative Colitis Low molecular weight fucoidan and standard care, Placebo and standard of care - Ulcerative Colitis (UC) | Phase 1 / Phase 2 | Enrolling by invitation | Allama Iqbal Medical College | 90 | 2026-08-01 | 2026-08-26 |
| Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD SPY001, SPY002, SPY003 - Ulcerative Colitis, Inflammatory Bowel Diseases | Phase 2 | Enrolling by invitation | Spyre Therapeutics, Inc. | 645 | 2026-06-08 | 2026-11-03 |
| Autism Spectrum Disorder (ASD) Neurodevelopmental Disorder With Issues Social Behavior, Communication Issues, GI Dysfunction. Study is Multimodal Interventions Targeting These Pathways With cSVF, Stored MSCs, FMT and Diet Modification. Role of Autoimmunity, Gut-brain Issues, & Issues Examined. Autologous MSC isolation, concentration, and cryopreservation of adult mesenchymal stem cells, Fecal Biomicrome Transplantation (FMT), Ketogenic RESET Diet Protocol - Autism Spectrum Disorder, Autism | Phase 1 / Phase 2 | Enrolling by invitation | Black Tie Medical, Inc. | 50 | 2026-04-30 | 2026-04-27 |
| Mesenteric Vascular Preconditioning Combined With Laparoscopic and Endoscopic Cooperative Surgery for Submucosal Tumor at the Gastroesophageal Junction laparoscopic and endoscopic cooperative surgery - Submucosal Tumor of Gastrointestinal Tract, Gastrointestinal Stromal Tumor (GIST) | Phase 2 | Enrolling by invitation | Peking University People's Hospital | 40 | 2026-04-01 | 2026-04-30 |
| Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma Nimotuzumab, camrelizumab, Albumin paclitaxel - Esophageal Squamous Cell Carcinoma | Phase 2 | Enrolling by invitation | Peking University | 48 | 2025-11-01 | 2025-12-31 |
| Low-dose Immunotherapy in Metastatic and Locally Advanced Colorectal and Gastric MSI/dMMR Cancers Low-dose nivolumab, Low-dose nivolumab with/without chemotherapy, Low-dose nivolumab combined with chemotherapy - Colorectal Cancer, Gastric Cancer | Phase 2 | Enrolling by invitation | Blokhin's Russian Cancer Research Center | 128 | 2025-06-03 | 2026-04-24 |
| XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI, Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI - Colorectal Cancer, Metastatic Colorectal Cancer With RAS Mutation | Phase 1 / Phase 2 | Enrolling by invitation | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 102 | 2025-05-23 | 2026-09-25 |
| Using CICS-1 and SPM-011 and ［18F］FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA BNCT, ［18F］FBPA - Thoracic Solid Malignant Tumor | Phase 1 / Phase 2 | Enrolling by invitation | Stella Pharma Corporation | 30 | 2025-04-10 | 2025-11-19 |
| Effectiveness of Probiotics for the Prevention of Gastrointestinal Toxicity in Children With Leukemia Lactobacillus casei, Lactobacillus rhamnosus, Bifidobacterium bifidum - Probiotics, Gastrointestinal Diseases | Phase 2 | Enrolling by invitation | National Institute of Pediatrics, Mexico | 120 | 2025-02-01 | 2025-03-14 |
| Evaluation of the Efficacy of Local Budesonide Treatment in Children with Crohn's Disease Located in the Esophagus And/or Stomach And/or Duodenum budesonide, omeprazole (proton pump inhibitor) - Crohn Disease (CD) | Phase 2 / Phase 3 | Enrolling by invitation | Medical University of Warsaw | 114 | 2024-07-30 | 2024-12-06 |
| Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors PET/CT （[18F]AlF-NOTA-PCP2）, [18F]AlF-NOTA-PCP2 PET/CT Imaging for PD-L1 Expression in Malignant Tumors - Glioblastoma (GBM), Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Enrolling by invitation | Man Hu | 100 | 2024-03-30 | 2025-03-30 |
| Prevention of Oral Mucositis and Improvement of Quality of Life for Patients With Breast Cancer Undergoing Adjuvant Radiotherapy Alginos Oral Suspension - Breast Carcinoma | Phase 2 | Enrolling by invitation | Taipei City Hospital | 90 | 2024-02-15 | 2025-05-06 |
| Long-term Efficacy and Safety of Fecal Microbiota Transplantation in Patients With Ulcerative Colitis Fecal microbiota transplantation (FMT) - Ulcerative Colitis, Fecal Microbiota Transplantation | Phase 2 / Phase 3 | Enrolling by invitation | Seoul National University Hospital | 30 | 2023-07-19 | 2025-09-12 |
| Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma paclitaxel, carboplatin, tislelizumab - Esophageal Squamous Cell Carcinoma | Phase 1 / Phase 2 | Enrolling by invitation | Qiu Guoqin | 30 | 2022-06-01 | 2024-03-12 |
Colitis, Ulcerative (3) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Colitis (2) · Colorectal Neoplasms (2) · Esophageal Neoplasms (2) · Esophageal Squamous Cell Carcinoma (2) · Anus Neoplasms (1) · Autism Spectrum Disorder (1) · Autistic Disorder (1) · Communication (1) · Crohn Disease (1) · Dysbiosis (1) · Esophagitis (1)
Digestive System Diseases (16) · Neoplasms (10) · Digestive System Neoplasms (8) · Gastrointestinal Neoplasms (8) · Intestinal Diseases (8) · Neoplasms by Site (8) · Colonic Diseases (6) · Neoplasms by Histologic Type (6) · Esophageal Diseases (5) · Gastroenteritis (5) · Head and Neck Neoplasms (4) · Neoplasms, Glandular and Epithelial (4) · Carcinoma (3) · Carcinoma, Squamous Cell (3)
Fecal Microbiota Transplantation (2) · Alginates (1) · Anti-Inflammatory Agents (1) · Budesonide (1) · Carboplatin (1) · Cisplatin (1) · Drug Therapy (1) · Folfox protocol (1) · Immunomodulation (1) · Laparoscopy (1) · Nivolumab (1) · Omeprazole (1) · Paclitaxel (1) · Proton Pump Inhibitors (1) · Radiotherapy (1)
Allama Iqbal Medical College (1) · Black Tie Medical, Inc. (1) · Blokhin's Russian Cancer Research Center (1) · Johns Hopkins University (1) · Man Hu (1) · Medical University of Warsaw (1) · National Institute of Pediatrics, Mexico (1) · Peking University (1) · Peking University People's Hospital (1) · Qiu Guoqin (1) · Seoul National University Hospital (1) · Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (1) · Spyre Therapeutics, Inc. (1) · Stella Pharma Corporation (1) · Taipei City Hospital (1)
China (5) · United States (4) · Mexico (2) · Poland (2) · South Korea (2) · Taiwan (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Chile (1) · Czechia (1) · Georgia (1) · Germany (1)
Christopher L Anker, MD (1) · Gerry Mullin, MD (1) · Man Hu, Dr. (1) · Rozina Shahadat Khan, MBBS, M.PHIL,MSPH, CHPE,PHDHND (1) · Sara Espinosa-Padilla, Ph.D. (1) · Yi-Sheng Chou, M.D (1) · Zhihao MM Lu, PHD (1)
PMID 11408503, PMID 11972517, PMID 14966830, PMID 15253677, PMID 17516870, PMID 17576459, PMID 19553647, PMID 21879172, PMID 23727426, PMID 23757085, PMID 24290319, PMID 24428625, PMID 24618152, PMID 24713845, PMID 24891990, PMID 25040088, PMID 25304690, PMID 25651996, PMID 26888258, PMID 28270698, PMID 28287336, PMID 28413626, PMID 28426102, PMID 28646338, PMID 29182564, PMID 29518185, PMID 30168576, PMID 31033786, PMID 31280227, PMID 31777071, PMID 31826366, PMID 38291578, PMID 38713298, PMID 9718381
2025 (1)